Phase 2 Alzheimer's Disease Trial, Recruiting NCT07012993 Sponsor: Akiva Mintz Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT07012993
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You must be able to understand and agree to the study procedures by signing a consent form
  • If you are a woman, you must not be pregnant or breastfeeding at the time of joining
  • If you are a woman who could become pregnant, you must have a negative pregnancy test before enrolling

Who may not be able to join:

  • People who have already received too much radiation from research-related scans (the total limit is 50 millisieverts, or mSv — confirm with trial site if you are unsure about your history)
  • People who have already taken part in this same study more than four times before
  • People who have severe fear of enclosed spaces (claustrophobia), long-term pain, or physical conditions affecting their bones or muscles that would make it impossible to complete the PET scan (a type of medical imaging)
  • Women who are pregnant or breastfeeding, or who cannot provide a negative pregnancy test
  • People who are not able to understand or agree to the study procedures and give their consent
  • Anyone whose health or situation the study doctor feels could put them at risk or affect the reliability of the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 973-255-4955

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Akiva Mintz
Registry
ClinicalTrials.gov
Start date
20 May 2025
Est. completion
30 June 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Signal-to-Noise Ratio (SNR); Contrast-to-Noise Ratio (CNR); Coefficient of Variation (COV); Spatial Resolution (Full Width at Half Maximum - FWHM); Target-to-Background Ratio (TBR); Qualitative Image Quality Score (Likert Scale); Inter-reader Agreement (Weighted Kappa Statistics)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov